New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
04:55 EDTLGND, LGND, LGND, MDCO, MDCO, MDCO, ESRX, ESRX, ESRX, NPSP, NPSP, NPSP, BDSI, BDSI, BDSI, FEIC, FEIC, FEIC, HUM, HUM, HUM, IDIX, IDIX, IDIX, SYK, SYK, SYK, STE, STE, STE, PRTA, PRTA, PRTABofA/Merrill to hold a conference
2014 Healthcare Conference to be held in Las Vegas on May 13-15.
News For LGND;STE;SYK;IDIX;HUM;FEIC;BDSI;NPSP;ESRX;MDCO;PRTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 24, 2015
07:41 EDTHUMHumana received DOJ request for information on Medicare
Subscribe for More Information
March 23, 2015
12:17 EDTHUMOn The Fly: Midday Wrap
Subscribe for More Information
09:07 EDTHUMSelect Medical agrees to acquire Concentra through JV with Welsh Carson
Subscribe for More Information
09:04 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
Humana (HUM) has reached a definitive agreement to sell the stock of its wholly-owned subsidiary, Concentra, to MJ Acquisition Corporation, a joint venture between Select Medical Holdings Corporation (SEM), an operator of specialty hospitals and outpatient rehabilitation clinics in the U.S., and Welsh, Carson, Anderson & Stowe XII, L.P., a private equity fund, for approximately $1.055B in cash, subject to customary adjustments. Humana acquired Concentra in December 2010. Subsequently, the assets of certain privately-operated Community Based Outpatient Clinics were transferred into Concentra. Additionally, Humana has divested certain Concentra non-core assets over the past four years. The decision to divest Concentra demonstrates the companyís commitment to its previously announced business portfolio review. Humana will continue performing its review of the alignment and return potential of businesses across the organization to ensure each supports the companyís integrated care delivery strategy and earns the appropriate return on invested capital. The Concentra transaction is anticipated to close during the second quarter of 2015 subject to Hart Scott Rodino regulatory clearance and customary closing conditions. Humana anticipates using the net proceeds from the transaction to advance its strategic growth priorities, to fund additional share repurchases under its existing $2 billion authorization and for general corporate purposes. Goldman, Sachs & Co. is acting as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP is acting as legal advisor to Humana. Concentra reported revenues for the year ended December 31, 2014 were approximately $1B. Humana anticipates the Concentra divestiture will be slightly dilutive to 2015 EPS excluding any one-time gain expected upon the close of the transaction.
09:02 EDTHUMHumana reiterates FY15 EPS view $8.50-$9.00, concensus $8.87
Subscribe for More Information
09:02 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
March 20, 2015
16:22 EDTPRTAOn The Fly: Closing Wrap
Subscribe for More Information
15:16 EDTBDSIBioDelivery Sciences April volatility elevated
Subscribe for More Information
14:20 EDTPRTAProthena retraces earlier gains, levels to watch
Subscribe for More Information
12:41 EDTPRTAOn The Fly: Midday Wrap
Stocks began the day sharply higher and have continued to tack on gains throughout the morning. The marketís move put the Nasdaq back above 5,000 and the S&P above 2,100. The market is undergoing quadruple witching, which occurs 4 times per year and typically is accompanied by high volume and volatility. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. The Baker Hughes U.S. rig count, which has been closely watched in recent months amid the protracted slide in oil prices, is expected at 1:00 pm EDT. The count of U.S. rigs stood at 1125 at the end of last week. In Europe, reports indicate German Chancellor Angela Merkel said Greece has agreed to send a list of overhauled reforms to European officials within days. COMPANY NEWS: Shares of Nike (NKE) advanced 4% following its Q3 earnings beat. Credit Suisse raised Nike's price target to $106 following the report, saying Nike's underlying futures growth remains in double-digits and preliminary FY16 guidance suggests management has been effective in managing currency headwinds... The shares of Biogen (BIIB) rallied 8% after the company reported results for an early stage study of its Alzheimer's drug, BIIB-037. The company announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. MAJOR MOVERS: Among the notable gainers was Prothena (PRTA), which surged 30% after announcing results from a Phase 1 single ascending dose study of its potential treatment of Parkinson's disease. Also higher was Darden Restaurants (DRI), which gained 4% after the owner of the Olive Garden and Long Horn restaurant chains reported earnings that beat expectations. Among the noteworthy losers was China's Youku Tudou (YOKU), which dropped 9% and was downgraded to Sell at Deutsche Bank after the company reported mixed Q4 results. Also lower was Theravance (THRX), which fell 7% after the company and partner GlaxoSmithKline (GSK) announced that an FDA advisory committee voted that the efficacy data for their Breo Ellipta inhaler provides substantial evidence of a clinically meaningful benefit in adults, however it voted against approval for the proposed indication in 12-17 year olds. INDEXES: Near midday, the Dow was up 189.04, or 1.05%, to 18,148.07, the Nasdaq was up 40.24, or 0.81%, to 5,032.62, and the S&P 500 was up 19.54, or 0.94%, to 2,108.81.
10:07 EDTPRTAHigh option volume stocks
Subscribe for More Information
10:00 EDTMDCOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:24 EDTPRTAOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
08:33 EDTPRTAProthena price target raised to $50 from $40 at RBC Capital
Subscribe for More Information
08:18 EDTHUMLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
March 19, 2015
18:58 EDTPRTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Mattress Firm (MFRM), up 5.2%... New York & Company (NWY), up 3.1%... Rally Software (RALY), up 1.4%... Nike (NKE), up 4.2%... Youku Tudou (YOKU), up 1%. ALSO HIGHER: Prothena (PRTA), up 39.3% after reporting positive results from Phase 1 study of PRX002... SeaWorld (SEAS), up 1% after naming Joel Manby as president and CEO. DOWN AFTER EARNINGS: AK Steel (AKS), down 9.1%.
16:14 EDTPRTAProthena report positive results from Phase 1 study of PRX002
Subscribe for More Information
16:06 EDTMDCOThe Medicines Co. initiated with a Neutral at Mizuho
Subscribe for More Information
March 17, 2015
09:25 EDTBDSIOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTESRXExpress Scripts has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO George Paz on March 18 at 11 am.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use